Recently, Binhui Biopharm announced that for BS001 injection, the first oncolytic virus drug candidate developed by the company's lysovirus (oHSV2) technology platform, a dose-expansion phase clinical trial in the melanoma indication is about to complete. The trial was conducted by Professor Guo Jun, Secretary General of the Chinese Society of Clinical Oncology (CSCO) and Chairman of the CSCO Melanoma Expert Committee, as the principal investigator (PI). Since its official launch at Beijing Cancer Hospital in October 2018, as of April 2021, clinical data showed that the objective remission rate (ORR) of BS001 injection for the treatment of melanoma reached 30%, the disease control rate (DCR) reached 50%, and the one-year survival rate (OS) was as high as 93%, showing excellent clinical efficacy, which is a good news to Chinese melanoma patients.

As a partner CRO for the project, Panacro provides a full range of services for clinical studies of oncolytic virus (oHSV2). Since the start of this project in 2018, the clinical medicine and statistics teams of Panacro have worked closely with Binhui Biopharm and Beijing Cancer Hospital to scientifically design the clinical trial protocol and strictly ensure the professionalism and operability of the top-level design of this clinical study.

The operation and execution team strictly followed the GCP specification and trial protocol, organized the implementation meticulously, and took full responsibility for the quality and progress of the clinical trial, ensuring that the clinical study procedures in this phase were compliant and the data were true and reliable.

"The clinical progress of Binhui Biopharm Biolysis Virus(oHSV2) project take the lead in China, and as the CRO team for the design and implementation of the clinical trial project of BS001 injection for melanoma, Panacro is very pleased with the promising results obtained from the preliminary collaboration. The birth of a new therapy may change the landscape of the melanoma treatment market in China. The Panacro project team also demonstrated rigorous working attitude, professional knowledge base, and excellent execution ability. In the future, Panacro will continue to help promote the Binhui Biopharm Biolysis Virus (oHSV2) project and continue to provide high-quality clinical services for sponsors,” said Du Xiaojian, Chief Medical Officer, Panacro.